Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 August 2022, including: planned US drug pricing legislation in focus; solid quarter but no Seagen Inc.  announcement for Merck & Co., Inc.; AbbVie Inc.’s Gonzalez sounds alarm over US pricing legislation; Alnylam Pharmaceuticals Inc. ready to expand in amyloidosis; and Boehringer Ingelheim GmbH on global Jardiance strategy.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Pharma Braces For Potential Landmark Moment For US Drug Price Controls" - Scrip, 2 Aug, 2022.)

(Also see "Merck’s Solid Quarter Doesn’t Soothe Seagen M&A Watchers" - Scrip, 28 Jul, 2022.)

(Also see "AbbVie’s Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal" - Scrip, 29 Jul, 2022.)

(Also see "Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results" - Scrip, 3 Aug, 2022.)

(Also see "Boehringer Will Go 'Wide, Broad, Fast, Strong' If Jardiance Hits CKD Bullseye" - Scrip, 2 Aug, 2022.)

 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel